Comparison of efficacy of Paclitaxel with Cisplatin when given weekly along with radiation in patients suffering from Head and Neck cancers.

Comparison of outcomes of weekly Paclitaxel versus weekly Cisplatin in Oral cavity, Oropharyngeal and Hypopharyngeal cancer patients with concurrent Radiation - A Randomized Controlled Trial.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009864

Enrollment

176

Registered

2017-09-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C040- Malignant neoplasm of anterior floor of mouth Health Condition 2: C131- Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect Health Condition 3: C01- Malignant neoplasm of base of tongue Health Condition 4: C060- Malignant neoplasm of cheek mucosa Health Condition 5: C020- Malignant neoplasm of dorsal surface of tongue Health Condition 6: C002- Malignant neoplasm of external lip, unspecified Health Condition 7: C050- Malignant neoplasm of hard palate Health C

Interventions

Intervention1: Drug Paclitaxel: It is a chemotherapy drug used in many types of cancers including Head and Neck cancers.In our study weekly paclitaxel 40mg per meter square is used along with radiatio

Eligibility

Inclusion criteria

Inclusion criteria: 1.all biopsy proven oral cavity, oropharyngeal and hypopharyngeal cancer patients are taken into trial 2.Normal liver function tests and normal hemogram reports 3.normal renal function tests should be there to include under the trial. 4 performance score according to ECOG scale should be more than or equal to 2

Exclusion criteria

Exclusion criteria: 1. patients with distant metastasis 2. patients with uncontrollable hypertension and diabetes. 3. history of previous oncological surgery for the same condition 4. history of previous irradiation to the same site

Design outcomes

Primary

Measure	Time frame
To assess loco regional control in patients of oral cavity, oro-pharyngeal and hypo pharyngeal cancers, treated with concurrent chemo radiation using weekly Paclitaxel or weekly Cisplatin. Timepoint: The outcome will be assessed three months after treatment.	—

Secondary

Measure	Time frame
To assess acute toxicities in patients treated with CCRT using weekly Paclitaxeland weekly cisplatin in oral cavity, oropharyngeal and hypo pharyngeal cancers.Timepoint: Acute toxicities will be assessed through out the course of treatment and within three weeks after treatment.	—

Countries

India

Contacts

Public ContactDr Parthasarathy V

Jawaharlal Institute of Postgraduate Medical Education and Research

dr_patchu2003@yahoo.co.in9443601748

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026